Ribociclib has been included in China's medical insurance to help breast cancer patients reduce their burden

Ribociclib, a drug branded under the trade name Kisqali, is an important treatment for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. It has attracted widespread attention in China, and recently received good news——The drug has been officially included in China’s National Medical Insurance List.

The implementation of this policy means that patients can enjoy reimbursement from medical insurance when purchasing ribociclib , thus greatly easing the financial pressure on patients. For many breast cancer patients, this is undoubtedly good news. It not only improves the availability of drugs, but also provides a strong guarantee for continued treatment.

However, it should be noted that the medical insurance reimbursement of ribociclib (ribociclib) is not for all breast cancer patients, but mainly for HR+/HER2- locally advanced or metastatic breast cancer patients, and it needs to be used in combination with an aromatase inhibitor as the initial endocrine therapy for female patients. The specific reimbursement amount and process may vary slightly depending on the region, so it is recommended that patients consult the local hospital or medical insurance department for detailed consultation.

The current market price of Ribociclib is relatively high, about more than 8,000 yuan per box. However, after being included in medical insurance, the actual payment of patients will be significantly reduced. In addition, in addition to imported original drugs, there is also a more affordable Indian version of ribociclib on the market. Its price is about 3,000 yuan, and its efficacy is equivalent to that of imported drugs. However, patients must ensure the legality of the drug when choosing it and use it under the guidance of a doctor.

In general, Ribociclib 's inclusion in medical insurance is a major progress in China's medical security system. It will bring hope of treatment and financial support to more breast cancer patients.